SCHEMBL5504492

SCHEMBL5504492

COc1cccc(-c2coc3cc(OC)ccc3c2=O)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.82
SMN1; SMN2 Q16637 9/20 0.82
RAB9A P51151 9/20 0.82
ALDH1A1 P00352 9/20 0.82
NPC1 O15118 8/20 0.82
MEN1 O00255 6/20 0.82
KMT2A Q03164 6/20 0.82
KDM4E B2RXH2 5/20 0.82
CYP3A4 P08684 4/20 0.82
HPGD P15428 4/20 0.82
TP53 P04637 3/20 0.82
PPARG P37231 2/20 0.81
PPARD Q03181 2/20 0.81
PPARA Q07869 2/20 0.81
XDH P47989 1/20 0.70
LMNA P02545 2/20 0.66
PIN1 Q13526 1/20 0.63
HSD17B10 Q99714 4/20 0.62
HDAC6 Q9UBN7 2/20 0.62
BCL2 P10415 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30527861 1.00 MAPT (0.82) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL2069068 0.91 MAPT (0.77) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL7499952 0.91 MAPT (0.77) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL762092 0.90 MAPT (1.00) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL2070726 0.90 PPARG (1.00) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL4366282 0.90 MAPT (0.74) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL3494129 0.89 MAPT (0.73) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL571576 0.87 XDH (0.84) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL30527851 0.86 MAPT (0.70) MAPTSMN1; SMN2RAB9AALDH1A1NPC1
SCHEMBL29085509 0.86 MAPT (0.70) MAPTSMN1; SMN2RAB9AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113512018-B Flavonoid compound and preparation method and application thereof 合肥工业大学 2023-07-18 CN disclosed
EP-1778656-A1 BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-05-02 EP disclosed
WO-2006023242-A1 BENZOXAZEPINE DERIVATIVES AS SELECTIVE ESTROGEN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-02 WO disclosed
US-20060040917-A1 Benzoxazepine derivatives as selective estrogen receptor modulators JANSSEN PHARMACEUTICA N.V. (BE) 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040917-A1 Benzoxazepine derivatives as selective estrogen receptor modulators GPER1, ESR2, ESR1 MAPT 1607/4885SMN1; SMN2 4276/4885RAB9A 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.